A. Rottoli et al., Should genetic analysis in newborn screening and a heterozygote test for hyperphenylalaninaemia be recommended? An Italian study, J MED SCREE, 6(4), 1999, pp. 193-194
Objective-To determine whether the introduction of genetic analysis for phe
nylalanine hydroxylase (PAH) deficiency into regional screening programmes
can be supported by the benefit-cost ratio.
Method-Tests for the genetic PAH locus were carried out in 151 patients wit
h hyperphenylalaninaemia originally from all of the Italian regions. PAH mu
tations were identified by extraction of genomic DNA from leucocytes (whole
blood in EDTA), PAH exon amplification was determined by polymerase chain
reaction, restriction enzyme analysis was carried out for some recognised m
utations, and DNA sequence analysis for the other mutations.
Results-It was found that the eight most common mutations in the population
accounted for 49% of the mutant alleles, which is well below the required
standard for effective population screening (90%).
Conclusions-Genetic screening for PAH deficiency in Italy does not increase
the sensitivity of the methodology and the benefit-cost ratio, and thus pr
ovides no advantage, particularly as the correlation between genotype and t
he metabolic phenotype needed to optimise dietary intervention is still bei
ng studied.